Pipeline

Pipeline

Advancing a compelling pipeline of next generation immune cell engagers

By leveraging our unique insights into gamma delta T cell biology, Cytospire is driving the development of novel, potent and well-tolerated immune cell engagers as treatments for patients with solid and liquid tumors.

Program

Description

Discovery

Preclinical

Clinical

Indication

CYT X300

EGFR x pan-γδ TCE

Your Content Goes Here

Solid tumors

CYT X600

TAA x pan-γδ TCE 

Your Content Goes Here

Heme tumors

CYT X400

TAA x pan-γδ TCE 

Your Content Goes Here

Solid tumors

CYT X500

Autoimmune antigen x pan-γδ TCE

Your Content Goes Here

Autoimmunity

Pipeline
CYT x300

CYT X300 is our first-in-class pan-gamma delta T cell engager targeting EGFR.

CYT X300 combines all the advantages of our pan-gamma delta engagers with the targeting of EGFR, one of the best understood, clinically precedented and compelling tumor associated antigens.

EGFR is the ideal antigen to prove the CYT X platform

EGFR Protein
Clinically validated antigen
EGFR expression unlocks large addressable unmet need
Intractable to CD3 T cell engagers
γδT cells enriched and drive responses in target indications
EGFR resistance mutations don’t impair CYT X300 mechanism of action

Clinically validated antigen

EGFR expression unlocks large addressable unmet need

Intractable to CD3 T cell engagers

γδT cells enriched and drive responses in target indications

EGFR resistance mutations don’t impair CYT X300 mechanism of action